NCT03676413View on ClinicalTrials.gov

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

PHASE3CompletedINTERVENTIONAL

Enrollment

451

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

August 2, 2019

Study Completion Date

June 30, 2020

Conditions

Asthma

Interventions

DRUG

Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals

new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study

DRUG

ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK

twice daily inhalation throughout the study

DRUG

Placebo

twice daily inhalation throughout the study

Trial Locations (1)

Unknown

BECRO Ltd., Athens

All Listed Sponsors

lead

Respirent Pharmaceuticals Co Ltd.

INDUSTRY

NCT03676413 - A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma | Biotech Hunter | Biotech Hunter